PIMREG and prostate carcinoma: CatS has recently emerged as a relevant biomarker in cancer with reports of association with poor prognosis in glioblastoma (Flannery et al, 2006) and with disease aggression in uveal melanoma (Paraoan et al, 2009), hepatocellular carcinoma (Xu et al, 2009) and prostate carcinoma (Fernandez et al, 2001; Lindahl et al, 2009).